7 results about "Antihistamine" patented technology

An antihistamine compound having the structure of formula (I), a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of the antihistamine compound having the structure of formula (I) and a pharmaceutically acceptable salt thereof in the treatment of diseases such as seasonal / perennial allergic rhinitis, allergic conjunctivitis, and urticaria. JPEG2025519827000061.jpg85170

Provided is a means for shortening the onset time of the action of a local anesthetic, an antihistamine, or the like in the oral mucosa. The micro-protrusion patch comprises a base plate and micro-protrusions erected on the base plate, and the micro-protrusion patch is made of water-insoluble thermoplastic polymer materials and used for being applied to oral mucosa. And a topical application system comprising the microprotrusion patch, a coating drug (a gel or ointment containing the drug, etc.), and an adhesive tape for backing, for shortening the action time of the drug in the oral mucosa.

The invention discloses a skin antibacterial and antipruritic pharmaceutical composition containing plant extracts and a preparation method thereof, the skin antibacterial and antipruritic pharmaceutical composition containing the plant extracts comprises the following components: at least two of the plant extracts selected from honeysuckle extracts, mint extracts, tea tree oil extracts and aloe extracts, an antibacterial agent selected from a natural antibacterial agent or a synthetic antibacterial and antipruritic agent, and a preservative selected from a natural antibacterial agent or a synthetic antibacterial and antipruritic agent. The invention relates to an anti-pruritic composition, which is prepared from an antihistamine agent or a natural anti-pruritic component, a carrier, a water-based gel, a cream or an oily substrate, and an additional additive, which is prepared from a humectant, a preservative and a pH (Potential of Hydrogen) regulator. During implementation, by optimizing the selection and proportion of the plant extracts and combining specific carriers and auxiliary components, the antibacterial and antipruritic effects are remarkably improved, and meanwhile, the side effect risk is reduced. According to the composition, the synergistic effect of various plant extracts is utilized, the skin permeability and durability are enhanced, and the composition is suitable for various skin problems such as eczema, dermatitis and mosquito bites. The preparation method is simple and efficient, is easy for industrial production, and has a wide market application prospect.

The present disclosure provides compositions, uses thereof, and methods for treating subjects with obesity and / or metabolic disorders. In aspects and embodiments, the method comprises administering an effective amount of one or more of a mast cell stabilizer and an H1-antihistamine, in combination with a non-steroidal anti-inflammatory drug (NSAID), either in the same or separate compositions.

Disclosed herein are methods of administering a Casitas B-lineage lymphoma proto-oncogene B inhibitor (CBL-Bi) for treating a cancer in a subject. Additionally disclosed herein are methods of administering a pre-treatment in combination with the CBL-Bi for treating a cancer in a subject.

The invention discloses a lactobacillus gasseri BDUP (Lactobacillus gasseri) strain and application of the lactobacillus gasseri BDUP strain in preparation of drugs for treating atopic dermatitis or eczema. The preservation number of the lactobacillus gasseri BDUP strain is CGMCC (China General Microbiological Culture Collection Center) No. 18357. Different from existing probiotics which take effect mainly by resisting histamine or regulating Th1 / Th2 balance, the invention discloses a unique nerve-immune bidirectional regulation mechanism of the BDUP strain for the first time, and the BDUP strain can significantly down-regulate expression levels of a neuropeptide P substance (Substance P), a calcitonin gene-related peptide (CGRP), a nerve growth factor (NGF) and a pruritus specific factor IL-31 in skin tissues, so that the BDUP strain can be used for treating skin pruritus. Therefore, neurogenic inflammation and a pruritus conduction pathway are effectively blocked. Animal experiments show that the BDUP strain can shorten the scratching time of eczema model mice by about 80%, the itching relieving and anti-inflammatory effects of the BDUP strain are equivalent to those of potent glucocorticoid, and the BDUP strain has no side effect. The invention provides a novel efficient biological treatment scheme for solving intractable pruritus caused by eczema.

The present invention is a method for improving atopic dermatitis, comprising administering to a subject in need thereof a composition comprising a low-molecular-weight fucoidan (LMF), wherein the weight-average molecular weight of the LMF is less than 3,000 Daltons. The composition of the present invention can effectively improve the area and severity of the lesion in patients with AD, as well as the itching symptoms (including insomnia symptoms caused by itching), and can significantly improve the SCORAD index of patients with AD. In addition, the composition of the present invention can reduce the patient's dependence on topical steroid ointments and / or oral antihistamines and reduce the AD-related immune parameters without increasing the biochemical indices of liver and kidney. Therefore, the composition of the present invention can be both effective and safe in the treatment of AD.